Livzon Pharmaceutical Group Inc. (LIVZON PHARMA, 01513) announced two senior board nominations to be voted on at the upcoming annual general meeting (AGM).

The Board has proposed Liu Daping, currently Vice President, as Executive Director and concurrently President for the 12th session of the Board. Liu, 39, holds a bachelor’s degree in pharmaceutics from China Pharmaceutical University and has managed production operations at multiple subsidiaries, including Shenzhen Haibin Pharmaceutical and Shenzhen TaiTai Pharmaceutical. He joined Livzon Pharma as Vice President in January 2024 and owns no company shares. If approved, Liu will receive an annual director’s fee of RMB0.10 million (pre-tax) in addition to his presidential remuneration.

Separately, Kang Li, 53, is nominated as Independent Non-Executive Director (INED) to replace outgoing INED Bai Hua, whose six-year term is expiring. Kang holds a doctorate in economics, is a certified public accountant, and serves as an associate professor at Zhongnan University of Economics and Law. Her current independent directorships include Shandong Sito Bio-technology (300583.SZ) and Wuhan Zhongke Tongda High-tech (688038.SH). Kang meets Hong Kong Listing Rule 3.13 independence criteria, holds no Livzon Pharma shares, and will receive an annual director’s fee of RMB0.12 million (pre-tax) upon appointment.

Both appointments will take effect from the date of shareholder approval at the AGM and run through the full term of the 12th Board session. The nominations were endorsed by the Board’s Nomination Committee at a meeting on 23 April 2026.